Silence Therapeutics (SLN) Receivables (2019 - 2025)

Silence Therapeutics (SLN) reported Receivables of $28000.0 for Q3 2025, down 67.06% sequentially from $85000.0 in Q2 2025.

Silence Therapeutics (SLN) Receivables (2019 - 2025) Analysis & Trends

Silence Therapeutics (SLN) has 7 years of Receivables data on file, last reported at $28000.0 in Q3 2025.

For the quarter ending Q3 2025, Receivables changed N/A year-over-year to $28000.0; the trailing twelve-month figure through Sep 2025 stood at $28000.0 (changed N/A YoY), and the FY2024 full-year result was $972000.0, up 243.48% from the prior year.
Receivables declined to $28000.0 in Q3 2025, from $85000.0 in the prior quarter.
In the past five years, Receivables ranged from a high of $1.1 million in Q4 2022 to a low of $28000.0 in Q3 2025.
A 5-year average of $418343.4 and a median of $282982.6 in 2023 frame the typical range for Receivables.
Across the five-year window, Receivables slumped 98.85% in 2021 and jumped 243.48% in 2024, its largest moves.
Tracing SLN's Receivables over 5 years: stood at $446191.5 in 2021, then jumped by 140.53% to $1.1 million in 2022, then plunged by 73.63% to $282982.6 in 2023, then jumped by 243.48% to $972000.0 in 2024, then plunged by 97.12% to $28000.0 in 2025.
Business Quant data shows SLN's Receivables at $28000.0 in Q3 2025, $85000.0 in Q2 2025, and $41000.0 in Q1 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Receivables (Qtr)
1	Oculis Holding AG	68,785.72 Bn	68,785.72 Bn	-	-
2	Nanobiotix	1,895.57 Bn	1,895.51 Bn	-	4.97 Mn
3	BeOne Medicines	471.35 Bn	466.56 Bn	1.35 Bn	938.02 Mn
4	NuCana	279.75 Bn	279.75 Bn	-	1.13 Mn
5	Vertex Pharmaceuticals	120.24 Bn	113.00 Bn	2.59 Bn	2.00 Bn
6	Regeneron Pharmaceuticals	67.80 Bn	59.04 Bn	3.31 Bn	5.73 Bn
7	Belite Bio	62.51 Bn	62.51 Bn	-	-
8	Argenx Se	57.38 Bn	57.38 Bn	1.41 Bn	1.93 Bn
9	Revolution Medicines	37.78 Bn	37.78 Bn	-	-
10	Silence Therapeutics	1.62 Bn	1.49 Bn	411,000.00	-

Download Data